French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings

Launched by FRENCH INNOVATIVE LEUKEMIA ORGANISATION · Oct 19, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are treated in everyday medical settings. The goal is to understand the real-world management of these conditions and see how different treatments affect patients over time. CLL is a type of blood cancer that often involves an increase in certain types of white blood cells, while SLL is similar but doesn’t involve a high cell count. The trial is looking at patients who need treatment for their CLL or SLL, whether they are newly diagnosed or have been previously treated.

To be eligible for this study, participants must be at least 18 years old and have CLL or SLL that requires treatment based on certain medical guidelines. Patients who have recently discussed their treatment options in a medical meeting and agreed to participate can join. Those in the study will not be given new treatments; instead, researchers will observe how their current treatments work in practice. This trial is important because it aims to gather information that could improve the care and outcomes for future patients with these types of leukemia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18-year old
• • CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation
• • Patient requiring therapy for immune events (autoimmune Thrombocytopenia and autoimmune hemolytic anemia) are eligible
• • Patients who have been informed verbally and in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control
• • All consecutive patients for whom a discussion in the setting of local or regional multidisciplinary collegial meeting (in french : réunion de concertation pluridisciplinaire / RCP) has retained the need for starting a therapeutic strategy (curative or palliative)
• • Patients with untreated or previously treated CLL/SLL are both eligible
• • Patients enrolled in a clinical trial can be included in this non-interventional cohort study
• • Patients requiring therapy for CLL/SLL-associated immune events only are also eligible
• Exclusion Criteria:
• • Patients with no need of therapy
• • Patients with asymptomatic Binet A CLL
• • Patient with Richter's syndrome at inclusion
• • Patient requiring immunoglobulin substitution (with no need of a more specific therapy)